AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$CSTL

MAETZOLD DEREK J sold $130K of CSTL

MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 6,214 shares of CASTLE BIOSCIENCES INC (CSTL) at $20.86 ($0.13M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAETZOLD DEREK J
Published Jun 3, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Bearish
medium confidence
Mentioned
$CSTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLBearishLow
01

Why it matters

The filing provides the first public disclosure of the CEO's recent share sale, a data point for insider‑monitoring strategies.

02

Market read

First‑report insider sale by the CEO, modest size, may cause slight negative sentiment.

03

What to watch

The 10b5‑1 plan pre‑arranges sales, reducing the signaling value of the transaction.

Relevance 3/10Novelty 3/10Timing: post‑market today

Background

Castle Biosciences Inc. (CSTL) is a clinical‑stage biotech focused on oncology diagnostics.

Company-level read

Ticker impact

$CSTLBearishMedium confidence
Context

SEC Form 4 shows CEO Derek Maetzold sold 6,214 shares for $129,605, reducing his stake to 21,479 shares.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

The sale is modest in size but involves the CEO, which can influence sentiment.

Market effects

Sector

Minimal impact on the biotech sector; only a single insider transaction.

Regional

No regional effect beyond the company's stock.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company outlook.

Key entities

  • person
    Derek J. Maetzold

    President & Chief Executive Officer of Castle Biosciences

  • company
    Castle Biosciences Inc.

    Biotech company listed on NASDAQ under ticker CSTL

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

SEP 28
$CSTLMedAI 8/10

Castle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.

rttnews.com2 min
AUG 8
$CSTLMedAI 8/10

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.

fool.com6 min
JUL 30
$CSTLHigh

CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to

SEC EDGAR 8-K6 min